Evidence map›Paper›PMID 32709788›Full record

ArticleIndian journal of ophthalmology2020

Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent.

Anuradha Pradhan, Anasua Ganguly, Milind N Naik, Akshay Gopinathan Nair, Savari Desai, Suryasnata Rath

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Commentary: Thyroid eye disease in India: A wake-up call?Indian journal of ophthalmology · 2020
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Anuradha PradhanOphthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.
Anasua GangulyOphthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, KVC Campus, Vijayawada, Andhra Pradesh, India.
Milind N NaikOphthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, KAR Campus, Hyderabad, Telangana, India.
Akshay Gopinathan NairDepartment of Oculoplastic Surgery and Ocular Oncology: Aditya Jyot Eye Hospital, Wadala, Mumbai, Maharashtra, India.
Savari DesaiP.D Hinduja National Hospital, Mahim and Hinduja Healthcare Surgical, Mumbai, Maharashtra, India.
Suryasnata RathOphthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.
Aditya Jyot Eye Hospital · INL V Prasad Eye Institute · INP. D. Hinduja Hospital and Medical Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the current practice patterns in the treatment of thyroid eye disease (TED) in Indian subcontinent through a web-based survey of members of Oculoplastics Association of India (OPAI). Methods: This was an online web-based questionnaire survey disseminated via monkeysurvey.com to all ratified active members of OPAI between May 1, 2016 and June 30, 2016. Questions encompassed the background, training, region, and experience of oculoplastic surgeons along with the management protocol of TED. Results: Of the 435 emails sent to OPAI members, 9 bounced and 180 (42.3%) responded within the study period. A large majority (96%) of respondents were oculoplastic surgeons practicing in India and the remaining practiced within South-East Asia. Two-thirds of respondents were oculoplastic surgeons with less than 10 years of clinical experience; 82% were fellowship trained in Oculoplasty. Almost all (99%) favored a multidisciplinary management of TED. A large majority routinely grade the severity (89%) and activity (87%) of disease before management. While corticosteroid remained the treatment of choice, 54% preferred immune-modulators as the second-line of therapy for recalcitrant TED. Three-quarters did not use orbital radiotherapy as a management modality in active TED owing to concerns over its efficacy and/or safety. Conclusion: The survey gives useful insights to the practice patterns of TED management in Indian subcontinent. Multidisciplinary approach and grading of disease severity and activity were the rule rather than exception among OPAI members. Immune modulation was the preferred steroid-sparing agent in recalcitrant disease. Orbital radiotherapy was an uncommon treatment choice.

Indexed as

Graves OphthalmopathyHumansIndiaInternetSurveys and QuestionnairesIndiaorbital decompressionsurveythyroid eye disease

Identifiers

PMID32709788
PMCPMC7640870
OpenAlexW3043824735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.